Patents by Inventor Dan H. Schulze
Dan H. Schulze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210277091Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: February 1, 2021Publication date: September 9, 2021Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
-
Patent number: 10941191Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: December 20, 2018Date of Patent: March 9, 2021Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, GLIKNIK INC.Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 10851154Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: June 30, 2016Date of Patent: December 1, 2020Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20190218275Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.Type: ApplicationFiled: December 20, 2018Publication date: July 18, 2019Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
-
Patent number: 10208105Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: February 20, 2018Date of Patent: February 19, 2019Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20180186862Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.Type: ApplicationFiled: February 20, 2018Publication date: July 5, 2018Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
-
Patent number: 9926362Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: April 10, 2017Date of Patent: March 27, 2018Assignees: Gliknik Inc., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20170218049Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.Type: ApplicationFiled: April 10, 2017Publication date: August 3, 2017Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
-
Publication number: 20160355570Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: June 30, 2016Publication date: December 8, 2016Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 9512208Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: September 20, 2013Date of Patent: December 6, 2016Assignees: GLIKNIK INC., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Patent number: 9512210Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: March 20, 2014Date of Patent: December 6, 2016Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20160280768Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: June 8, 2016Publication date: September 29, 2016Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20150056185Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: March 20, 2014Publication date: February 26, 2015Applicants: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
-
Publication number: 20140335075Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: December 17, 2013Publication date: November 13, 2014Inventors: Scott E. Strome, Dan H. Schulze, David S. Block
-
Publication number: 20140105913Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: September 20, 2013Publication date: April 17, 2014Applicants: GLIKNIK, INC., University of Maryland, BaltimoreInventors: Scott E. STROME, Dan H. Schulze, David S. Block
-
Patent number: 8680237Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: GrantFiled: May 30, 2008Date of Patent: March 25, 2014Assignees: Gliknik Inc., University of Maryland, BaltimoreInventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
-
Publication number: 20120309941Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: May 11, 2012Publication date: December 6, 2012Applicants: GLIKNIK, INC., UNIVERSITY OF MARYLAND, BALTIMOREInventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
-
Publication number: 20100239633Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.Type: ApplicationFiled: May 30, 2008Publication date: September 23, 2010Applicant: UNIVERSITY OF MARYLAND BALTIMOREInventors: Scott E. Strome, Dan H. Schulze, David S. Block